Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Knox, Susan J.
508  Ergebnisse:
Personensuche X
?
1

Canis Familiaris Papillomavirus Type 26: A Novel Papillomav..:

Munday, John S. ; Bond, Sarah D. ; Piripi, Susan..
Viruses.  16 (2024)  4 - p. 595 , 2024
Link: https://doi.org/10.3390/..
 
?
2

Bilateral Rasmussen Encephalitis: Good Outcome Following He..:

Trapp, Noah ; Co, Dominic O. ; Rebsamen, Susan...
Pediatric Neurology.  151 (2024)  - p. 1-4 , 2024
Link: https://doi.org/10.1016/..
 
?
3

Family and community resilience: a Photovoice study:

Tan, Yvonne ; Pinder, Danielle ; Bayoumi, Imaan...
International Journal for Equity in Health.  23 (2024)  1 - p. , 2024
Link: https://doi.org/10.1186/..
 
?
4

Antibody agonists trigger immune receptor signaling through..:

Lippert, Anna H. ; Paluch, Christopher ; Gaglioni, Meike...
Immunity.  57 (2024)  2 - p. 256-270.e10 , 2024
Link: https://doi.org/10.1016/..
 
?
5

CALGB 80802 (Alliance): Impact of Sorafenib with and withou..:

Abou-Alfa, Ghassan K. ; Geyer, Susan M. ; Nixon, Andrew B....
Cancer Research Communications.  4 (2024)  3 - p. 682-690 , 2024
Link: https://doi.org/10.1158/..
 
?
6

TABLE 2 from CALGB 80802 (Alliance): Impact of Sorafenib wi..:

Ghassan K. Abou-Alfa ; Susan M. Geyer ; Andrew B. Nixon...
doi:10.1158/2767-9764.25359897.v1.  , 2024
Link: https://doi.org/10.1158/..
 
?
7

TABLE 2 from CALGB 80802 (Alliance): Impact of Sorafenib wi..:

Ghassan K. Abou-Alfa ; Susan M. Geyer ; Andrew B. Nixon...
doi:10.1158/2767-9764.25359897.v1.  , 2024
Link: https://doi.org/10.1158/..
 
?
8

Supplementary Figure 4 from CALGB 80802 (Alliance): Impact ..:

Ghassan K. Abou-Alfa ; Susan M. Geyer ; Andrew B. Nixon...
doi:10.1158/2767-9764.25359906.v1.  , 2024
Link: https://doi.org/10.1158/..
 
?
9

TABLE 1 from CALGB 80802 (Alliance): Impact of Sorafenib wi..:

Ghassan K. Abou-Alfa ; Susan M. Geyer ; Andrew B. Nixon...
doi:10.1158/2767-9764.25359903.v1.  , 2024
Link: https://doi.org/10.1158/..
 
?
10

Supplementary Figure 3 from CALGB 80802 (Alliance): Impact ..:

Ghassan K. Abou-Alfa ; Susan M. Geyer ; Andrew B. Nixon...
doi:10.1158/2767-9764.25359909.v1.  , 2024
Link: https://doi.org/10.1158/..
 
?
11

Supplementary Figure 1 from CALGB 80802 (Alliance): Impact ..:

Ghassan K. Abou-Alfa ; Susan M. Geyer ; Andrew B. Nixon...
doi:10.1158/2767-9764.25359918.v1.  , 2024
Link: https://doi.org/10.1158/..
 
?
12

FIGURE 2 from CALGB 80802 (Alliance): Impact of Sorafenib w..:

Ghassan K. Abou-Alfa ; Susan M. Geyer ; Andrew B. Nixon...
doi:10.1158/2767-9764.25359924.v1.  , 2024
Link: https://doi.org/10.1158/..
 
?
13

FIGURE 2 from CALGB 80802 (Alliance): Impact of Sorafenib w..:

Ghassan K. Abou-Alfa ; Susan M. Geyer ; Andrew B. Nixon...
doi:10.1158/2767-9764.25359924.v1.  , 2024
Link: https://doi.org/10.1158/..
 
?
14

Supplementary Figure 1 from CALGB 80802 (Alliance): Impact ..:

Ghassan K. Abou-Alfa ; Susan M. Geyer ; Andrew B. Nixon...
doi:10.1158/2767-9764.25359918.v1.  , 2024
Link: https://doi.org/10.1158/..
 
?
15

Supplementary Figure 4 from CALGB 80802 (Alliance): Impact ..:

Ghassan K. Abou-Alfa ; Susan M. Geyer ; Andrew B. Nixon...
doi:10.1158/2767-9764.25359906.v1.  , 2024
Link: https://doi.org/10.1158/..
 
1-15